Introduction

Sarcoidosis is a granulomatous disease with an incidence of up to 18 in 100,000 in some populations. Symptoms range from asymptomatic benign lesions to organ failure, with up to 90% of patients presenting with lung involvement. Sarcoidosis is often a diagnosis of exclusion: inflammation, lymphadenopathy, and sterile granulomata without an identifiable cause. Granuloma formation occurs in primary immunodeficiencies, but the full landscape of these deficiencies and their association with sarcoid is not fully understood.

Results

We looked retrospectively at patients initially diagnosed with sarcoidosis referred to the National Institutes of Health (NIH). Many people had refractory inflammation or had a diagnosis of sarcoidosis in the setting of other immune dysfunction such as common variable immunodeficiency (CVID). Within this group of 37 patients with completed whole-genome or whole-exome sequencing, 22 had pathogenic variants, likely pathogenic variants, or variants of unknown significance in relevant candidate genes including SP110, GATA2, NFKBIA, NFKB1, IRF8, CTLA-4, NCF1, SLC26A9, RFX5, MEFV, GFI1, PLCG2, STAT1, BACH2, IKZF3, JAK1, ADCY10, and STXBP2.

Conclusion

This study highlights the diseases often gathered under the diagnosis “sarcoid”. Prior studies have highlighted immune dysregulation within multiple pathways, including the interferon-gamma (IFN-γ) response pathway (GATA2, STAT1, NFKBIA, and IRF8), Th17.1 signaling (STAT1 and IRF8), and inflammasome response (IRF8, MEFV, and PLCG2), as being important in granuloma formation. Numerous mutations within this cohort have previously been associated with common immunodeficiencies (RFX5, NFKBIA, SP110, and IKZF3) or predominant antibody deficiencies (NFKB1). This cohort also showed defects of phagocyte number or function (GFI1, NCF1, and GATA2). Within this study, two variants were identified that are not associated with immunodeficiencies, including SLC26A9, an ion transporter for chloride previously identified in atypical cystic fibrosis, and ADCY10, a catalyst for the formation of cAMP. Though it is possible that some of these variants may not be causal or even relevant to the formation of granulomas, this cohort shows how some patients presenting with lymphadenopathy and sterile granulomata in various organs were identified to have Mendelian traits underlying their diagnoses of sarcoidosis.

Table 1.
Subject IDGenetic Defect IdentifiedAllele Frequency gnomAD v4.1.0Classification (ClinVar)ZygosityCADD ScoreInheritance PatternOrgan InvolvementInfection History
NFKBIA (IkBa) (c.691G>T, p.Asp231Tyr) 4.7e-5 VUS Het 27.3 AD CNS, Exocrine, Cutaneous NTM, EBV 
CTLA4 (c.567+5G>C) Pathogenic Het 26 AD Ocular, LN, Cutaneous, Pulmonary  
No defect identified      Ocular, Cutaneous, Pulmonary EBV 
NCF1 (p47phox Deficient CGD) (c.75_76del, p.Tyr26fs) 8.5e-4 Pathologic Homo 35 AR Pulmonary, Exocrine, LN S. capitis 
No defect identified      Cutaneous Sphingomonas paucimobilis 
No defect identified      Pulmonary M. avium 
No defect identified      Pulmonary, Neuro, LN JCV 
No defect identified      Pulmonary disseminated M. tilbergii 
11 NCF1 (p47phox Deficient CGD) (c.75_76del, p.Tyr26fs) 8.5e-4 Pathologic Homo 38 AR Pulmonary  
12 NCF1 (p47phox Deficient CGD) (c.75_76del, p.Tyr26fs) 8.5e-4 Pathologic Homo 38 AR MSK, Ocular, Splenic A. fumigatus 
14 1q41 222762100-224070013   Het   Hepatic, Pulmonary S. pneumo 
1.308 Mb-1.636 Mb Loss 
IFIH1 
NOD2 
LRBA 
FAT4 
KMT2D 
15 SP110 (c.1428_1429del, p.Tyr476Ter) 1.8e-6 Not Reported Het 34 AR Cutaneous M. chelonae 
16 SLC26A9 (c.1459G>A, p.Ala487Thr) 6.9e-5 Not Reported Het 20.8  Pulmonary MAC 
17 GATA2 (c.1021_1024dup, p.Ala342GlyfsTer43) Pathologic Het NA AD Pulmonary  
18 No defect identified      Pulmonary, Cutaneous  
19 IRF8 (c. 536C>T, p.Ala179Val) 6.5e-6 VUS Het 17.54 AR/AD Neuro MAC 
20 No defect identified      Pulmonary, GI MAC 
23 GATA2 (c.1021_1024dup, p.Ala342GlyTer43) Pathogenic Het NA AD BM  
25 STXBP2 (c.1001 C>T, p.Pro334Leu) 4e-5 Likely pathogenic Homo 29.9 AR Hepatic  
26 No defect identified      Pulmonary  
27 No defect identified      Pulmonary  
28 NFKB1 (c.1513A>C, p.Lys505Gln) 6.85e-7 VUS Het 26.2 AD Pulmonary, Cardiac  
29 RFX5 (c.353+2T>G) 1.8e-4 Likely pathogenic Het 33 AR Pulmonary, Cutaneous  
30 IKZF3 (c.244G>A, p.Glu82Lys) 1.4e-4 VUS Het 23.6 AD Hepatic, Ocular Recurrent Pneumonia 
31 No defect identified      Pulmonary EBV 
32 No defect identified      Cardiac  
33 No defect identified      Neuro VZV 
34 MEFV (c.289C>A, p.Gln97Lys) 9.43e-5 VUS Het 9.8 AD/AR Pulmonary, Hepatic  
35 GFI1 (c.200G>A, p.Arg67Lys) 3.4e-5 VUS Het 21.2 AR Pulmonary Aspergillus, pneumocystis 
36 PLCG2 (c.2931C>G, p.Tyr977Ter) 6.19e-7 VUS Het 38 AD Pulmonary, Splenic, Cutaneous Recurrent sinusitis 
37 STAT1 (c.736G>A, p.Ala246Thr) VUS Het 24 AD Pulmonary Histoplasmosis 
38 BACH2 (c.2327 C>T, p.Pro776Leu) 1.8e-5 VUS Het 16.9 AD Pulmonary  
39 No defect identified      Pulmonary  
40 ADCY10 (c.4477del, p.Leu1493SerfsTer24) 3e-4 Pathogenic Het 33 AD Pulmonary  
41 No defect identified      Pulmonary  
42 No defect identified      Cardiac  
43 JAK1 (c.1078C>T, p.Arg360Trp) 5.9e-5 VUS Het 25.1 AD/AR T1DM, Pulmonary, Ocular Histoplasmosis 
Subject IDGenetic Defect IdentifiedAllele Frequency gnomAD v4.1.0Classification (ClinVar)ZygosityCADD ScoreInheritance PatternOrgan InvolvementInfection History
NFKBIA (IkBa) (c.691G>T, p.Asp231Tyr) 4.7e-5 VUS Het 27.3 AD CNS, Exocrine, Cutaneous NTM, EBV 
CTLA4 (c.567+5G>C) Pathogenic Het 26 AD Ocular, LN, Cutaneous, Pulmonary  
No defect identified      Ocular, Cutaneous, Pulmonary EBV 
NCF1 (p47phox Deficient CGD) (c.75_76del, p.Tyr26fs) 8.5e-4 Pathologic Homo 35 AR Pulmonary, Exocrine, LN S. capitis 
No defect identified      Cutaneous Sphingomonas paucimobilis 
No defect identified      Pulmonary M. avium 
No defect identified      Pulmonary, Neuro, LN JCV 
No defect identified      Pulmonary disseminated M. tilbergii 
11 NCF1 (p47phox Deficient CGD) (c.75_76del, p.Tyr26fs) 8.5e-4 Pathologic Homo 38 AR Pulmonary  
12 NCF1 (p47phox Deficient CGD) (c.75_76del, p.Tyr26fs) 8.5e-4 Pathologic Homo 38 AR MSK, Ocular, Splenic A. fumigatus 
14 1q41 222762100-224070013   Het   Hepatic, Pulmonary S. pneumo 
1.308 Mb-1.636 Mb Loss 
IFIH1 
NOD2 
LRBA 
FAT4 
KMT2D 
15 SP110 (c.1428_1429del, p.Tyr476Ter) 1.8e-6 Not Reported Het 34 AR Cutaneous M. chelonae 
16 SLC26A9 (c.1459G>A, p.Ala487Thr) 6.9e-5 Not Reported Het 20.8  Pulmonary MAC 
17 GATA2 (c.1021_1024dup, p.Ala342GlyfsTer43) Pathologic Het NA AD Pulmonary  
18 No defect identified      Pulmonary, Cutaneous  
19 IRF8 (c. 536C>T, p.Ala179Val) 6.5e-6 VUS Het 17.54 AR/AD Neuro MAC 
20 No defect identified      Pulmonary, GI MAC 
23 GATA2 (c.1021_1024dup, p.Ala342GlyTer43) Pathogenic Het NA AD BM  
25 STXBP2 (c.1001 C>T, p.Pro334Leu) 4e-5 Likely pathogenic Homo 29.9 AR Hepatic  
26 No defect identified      Pulmonary  
27 No defect identified      Pulmonary  
28 NFKB1 (c.1513A>C, p.Lys505Gln) 6.85e-7 VUS Het 26.2 AD Pulmonary, Cardiac  
29 RFX5 (c.353+2T>G) 1.8e-4 Likely pathogenic Het 33 AR Pulmonary, Cutaneous  
30 IKZF3 (c.244G>A, p.Glu82Lys) 1.4e-4 VUS Het 23.6 AD Hepatic, Ocular Recurrent Pneumonia 
31 No defect identified      Pulmonary EBV 
32 No defect identified      Cardiac  
33 No defect identified      Neuro VZV 
34 MEFV (c.289C>A, p.Gln97Lys) 9.43e-5 VUS Het 9.8 AD/AR Pulmonary, Hepatic  
35 GFI1 (c.200G>A, p.Arg67Lys) 3.4e-5 VUS Het 21.2 AR Pulmonary Aspergillus, pneumocystis 
36 PLCG2 (c.2931C>G, p.Tyr977Ter) 6.19e-7 VUS Het 38 AD Pulmonary, Splenic, Cutaneous Recurrent sinusitis 
37 STAT1 (c.736G>A, p.Ala246Thr) VUS Het 24 AD Pulmonary Histoplasmosis 
38 BACH2 (c.2327 C>T, p.Pro776Leu) 1.8e-5 VUS Het 16.9 AD Pulmonary  
39 No defect identified      Pulmonary  
40 ADCY10 (c.4477del, p.Leu1493SerfsTer24) 3e-4 Pathogenic Het 33 AD Pulmonary  
41 No defect identified      Pulmonary  
42 No defect identified      Cardiac  
43 JAK1 (c.1078C>T, p.Arg360Trp) 5.9e-5 VUS Het 25.1 AD/AR T1DM, Pulmonary, Ocular Histoplasmosis 

This abstract is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by-nc-nd/4.0/).